CLINICAL_TRIALS
trial_result
· 2021-10-14
Clinical Trial Update: Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus [Phase 3]
Summary
Phase 3 extension study evaluating IV CR845 for moderate-to-severe pruritus in hemodialysis patients has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cara Therapeutics, Inc. | Conditions: Uremic Pruritus | Phase 3 | Status: COMPLETED | Results posted: 2021-10-14